MGA on Twitter
MGA on Facebook
MGA on Instagram
MGA logo

Clinical Trials

KATALYST MG                

 Dr. Pasnoor

University of Kansas Health Center

ClinicalTrials.gov Identifier: NCT06064695

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

Experimental: N/A- Device

All participants will receive the WB-EMS Exercise intervention 2 times per week for 4 weeks. Participants will only perform Level 1 exercise programs (simple movements) in the "Strength" Training Mode.


18+ gMG via sero+ test or sero- test with clinical symptoms consistent with gMG


Total enrollment: 16 participants

 For more information contact:
Abby Davis adavis54@kumc.edu

ME & MG Open


Eligibility Critiera
Aged 18 + years old


Diagnosis of gMG with positive serologic test for anti-AChR autoantibody at screening who has read the information sheet and signed the informed consent form
Owns a personal smartphone which version is above 14 for IOS and 8 for Android included
Able to use a smartphone
Able to perform the ME&MG tests (based on investigator's judgment)
Able to read language in which the mobile application is available (English, Spanish, German) and able to understand pictograms

For more information click here.

The MGA maintains communication with representatives from clinical research studies in efforts to keep the public informed about potential trials MG patients can participate in. Take a look at some of the latest studies in our area below or visit the clinical trials database to discover all the research studies conducted around the world.

ALXN1720 – MG           

PI: Dr. Dimachkie                                                                      University of Kansas Health Center                            ClinicalTrials.gov Identifier: NTC


A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis


Experimental: ALXN1720
Participants will receive a weight-based maintenance treatment with ALXN1720 on Day 1, followed by weight-based maintenance treatment of ALXN1720 on Week 1 (Day 8) and once every week (Q1W) thereafter for a total of 26 weeks. Following this randomized controlled treatment (RCT) period, all participants will receive ALXN1720 in an open-label extension (OLE) period of 96 weeks.
Placebo Comparator: Placebo
Participants will receive placebo during the 26-week RCT period, after which they will enter the OLE period of the study and receive ALXN1720.


Total Enrollment: 254 participants


For more information:
Nick Staudenmier nstaudenmier@kumc.edu

MOM-M281-011    

Dr. Farmakidis 

University of Kansas Medical Center

ClinicalTrials.gov Identifier: NCT04951622
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis

Experimental: Nipocalimab

Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase.
Nipocalimab will be administered as an IV infusion
Total enrollment: 198 participants

For more information contact:
Ali Russo aciersdorff@kumc.edu

DAS-MG                           

Dr. Dimachkie          

University of Kansas Health Center  

ClinicalTrials.gov Identifier: NCT04226170

A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given with Ondansetron to Subjects with anti-AchR positive Myasthenia Gravis

Experimental: Pyridostigmine

Group A: Patients currently taking pyridostigmine and experiencing pyridostigmine-related gastrointestinal (GI) adverse events (AEs) within the past 7 days

Pyridostigmine + Ondansetron will be administered as an oral tablet


Total enrollment: 24 participants


For more information contact:
Lilli Saavedra lsaavedra2@kumc.edu

ALXN2050 - MG
Eligibility Criteria
AGES ELIGIBLE FOR STUDY
18 Years and older (ADULT, OLDER_ADULT)
Key Inclusion Criteria:
Diagnosed with MG at least 3 months (90 days) prior to the date of the Screening Visit. Confirmation of MG must be made via the following:
Positive serologic test for anti AChR antibodies at the Screening Visit, and
Abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation, or
Positive response to an AChEI test (eg, edrophonium chloride test), or
Improvement of signs or symptoms related to MG during treatment with an oral AChEI, as determined by the treating physician
Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at the Screening Visit.
MG-ADL total score must be ≥ 5 (with at least 50% of the score attributed to non-ocular elements) at the Screening Visit and at randomization (Day 1).
Participants receiving treatment with protocol-specified immunosuppressive therapies, corticosteroids, or acetylcholinesterase inhibitors must have been receiving treatment and on a stable dose prior to the date of the Screening Visit, with no changes to the regimen expected during screening, the PEP, and/or the ETP.

Key Exclusion Criteria:
Estimated glomerular filtration rate ≤ 30 milliliters/minute/1.73 squared meters during Screening calculated by Chronic Kidney Disease Epidemiology Collaboration.
History of thymectomy, thymomectomy, or any other thymic surgery within 12 months prior to the Screening Visit.
Any untreated thymic malignancy, carcinoma, or thymoma. Participants with a history of treated thymic malignancy or carcinoma are eligible for enrollment if they meet pre-specified conditions outlined in the protocol.
Clinical features consistent with Clinical Deterioration at the time of the Screening Visit or at any time during the Screening Period prior to randomization (Day 1).

Use of the following within the time periods specified below:

Intravenous immunoglobulin G or subcutaneous immunoglobulin within the 4 weeks (28 days) prior to the Screening Visit.
Use of tacrolimus or cyclosporine within the 4 weeks (28 days) prior to the Screening Visit.

Recruiting for children  
Argenx                                                                                                      ClinicalTrials.gov Identifier: NCT05374590


Evaluating Long-term Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis


A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Ages 2-18

Contact: Sabine Coppieters, MD 857-350-4834 ClinicalTrials@argenx.com
 ​​​​
Recruiting in St. Louis, Missouri & Little Rock, Arkansas

Cartesian MG-001                        

Dr. Pasnoor 

ClinicalTrials.gov Identifier: NCT04146051

Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)

Experimental: Descartes-08

In Part 3, the primary objective is to compare the effect of Descartes-08 versus placebo, as measured by the change in MG ADL score from baseline to Week 12.
Descartes will be administered as a tablet
Total enrollment: 30 participants

 For more information contact:
Ali Russo aciersdorff@kumc.edu

Janssen                            

PI: Dr. Farmakidis

University of Kansas Health Center                          

ClinicalTrials.gov Identifier: NCT05265273


An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis


Experimental: Nipocalimab
Participants aged 2 to less than [<] 18 years of age will receive nipocalimab once every two weeks for 24 weeks. After Week 24, all participants will have the option to enroll in long term extension (LTE).
Nipocalimab will be administered as an IV infusion


Total enrollment: 12 participants


For more information contact:
Katie Lillig  kjennens2@kumc.edu 

Cabaletta Bio             

PI: Dr. Dimachkie                                                          University of Kansas Health Center                Clinicaltrials.gov identifier: NCT05451212


A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis


Experimental: MuSK-CAART
Cohort A: Infusion of MuSK-CAART at various dose levels with or without pre-treatment (6 groups planned).
Cohort B: Infusion of MuSK-CAART at the dose regimen selected from Part A


Total: 24 patients


For more information contact:
Andrew Heim aheim2@kumc.edu  

Immunovant MG                         

PI: Dr. Pasnoor

University of Kansas Health Center

ClinicalTrials.gov Identifier: NCT05403541


A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)


Experimental: Batoclimab
Period 1 arms:
Batoclimab 680 mg SC weekly
Batoclimab 340 mg SC weekly
Matching Placebo SC
Period 2 arms:
Batoclimab 340 mg SC weekly
Batoclimab 340 mg SC bi-weekly
Matching Placebo SC
Total enrollment: 210 participants
For more information:
Nick Staudenmier nstaudenmier@kumc.edu

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)


Eligibility Critiera
Child, Adult, Older Adult


Diagnosis of gMG confirmed by a positive serologic test for anti-AChR antibodies (Abs) obtained at Screening and/or during Screening Period
Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to Class IV at Screening
Participants receiving treatment must be on a stable dosing regimen of adequate duration prior to Screening and during the Screening Period.
Eculizumab-experienced participants must have been enrolled and treated with eculizumab in Study ECU-MG-303 for at least 6 months (180 days) and must have been on a stable dose for ≥ 2 months (60 days) prior to Screening.
All participants must be vaccinated against meningococcal infection

For more information click here.